1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis ( IPF ) preserved lung function...
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening...
First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from ...
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook